Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Pustular and erythrodermic psoriasis can be a debilitating and recalcitrant disease which may result in secondary complications such as sepsis, electrolyte imbalance, renal failure, and heart failure. We report a case of a 46-year-old patient with life-threatening erythrodermic psoriasis who responded rapidly to intravenous infliximab.
Lewis
Thomas G
TG
Department of Dermatology, Henry Ford Hospital, Detroit, MI 48202, USA.
Tuchinda
Chanisada
C
Lim
Henry W
HW
Wong
Henry K
HK
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab